JP2005513016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513016A5 JP2005513016A5 JP2003544012A JP2003544012A JP2005513016A5 JP 2005513016 A5 JP2005513016 A5 JP 2005513016A5 JP 2003544012 A JP2003544012 A JP 2003544012A JP 2003544012 A JP2003544012 A JP 2003544012A JP 2005513016 A5 JP2005513016 A5 JP 2005513016A5
- Authority
- JP
- Japan
- Prior art keywords
- sulfonamide
- indol
- naphthalene
- group
- structural formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 13
- VDZROAIEYLMUAT-UHFFFAOYSA-N n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(CC)CC)=CC=C21 VDZROAIEYLMUAT-UHFFFAOYSA-N 0.000 claims description 4
- JYFZTHMGIJASIF-NTEUORMPSA-N (e)-n-[3-[(4-methylpiperazin-1-yl)methyl]-1h-indol-5-yl]-2-phenylethenesulfonamide Chemical compound C1CN(C)CCN1CC(C1=C2)=CNC1=CC=C2NS(=O)(=O)\C=C\C1=CC=CC=C1 JYFZTHMGIJASIF-NTEUORMPSA-N 0.000 claims description 2
- YRFRIJABNSLKIC-FYWRMAATSA-N (e)-n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]-2-phenylethenesulfonamide Chemical compound C1=C2C(CCN(CC)CC)=CNC2=CC=C1NS(=O)(=O)\C=C\C1=CC=CC=C1 YRFRIJABNSLKIC-FYWRMAATSA-N 0.000 claims description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- QBEDVKUOBOOQJR-UHFFFAOYSA-N 3,5-dichloro-n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]benzenesulfonamide Chemical compound C1=C2C(CCN(CC)CC)=CNC2=CC=C1NS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 QBEDVKUOBOOQJR-UHFFFAOYSA-N 0.000 claims description 2
- XQIZCPRJWQBHCO-UHFFFAOYSA-N 5-chloro-3-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]-1-benzothiophene-2-sulfonamide Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=C(C)C2=CC(Cl)=CC=C2S1 XQIZCPRJWQBHCO-UHFFFAOYSA-N 0.000 claims description 2
- GPWFXKQDOCDPIO-UHFFFAOYSA-N 5-chloro-3-methyl-n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]-1-benzothiophene-2-sulfonamide;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=C(C)C2=CC(Cl)=CC=C2S1 GPWFXKQDOCDPIO-UHFFFAOYSA-N 0.000 claims description 2
- PREWUSRAKQXGHO-UHFFFAOYSA-N 5-chloro-3-methyl-n-[3-(2-morpholin-4-ylethyl)-1h-indol-5-yl]-1-benzothiophene-2-sulfonamide Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)NC(C=C12)=CC=C1NC=C2CCN1CCOCC1 PREWUSRAKQXGHO-UHFFFAOYSA-N 0.000 claims description 2
- HIGZEHKSXXYSGV-UHFFFAOYSA-N 5-chloro-3-methyl-n-[3-(2-pyrrolidin-1-ylethyl)-1h-indol-5-yl]-1-benzothiophene-2-sulfonamide Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)NC(C=C12)=CC=C1NC=C2CCN1CCCC1 HIGZEHKSXXYSGV-UHFFFAOYSA-N 0.000 claims description 2
- HYKSBOYHYALPPR-UHFFFAOYSA-N 5-chloro-3-methyl-n-[3-[(4-methylpiperazin-1-yl)methyl]-1h-indol-5-yl]-1-benzothiophene-2-sulfonamide Chemical compound C1CN(C)CCN1CC(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=C(C)C2=CC(Cl)=CC=C2S1 HYKSBOYHYALPPR-UHFFFAOYSA-N 0.000 claims description 2
- IXFIZZJAUYTVFQ-UHFFFAOYSA-N 5-chloro-n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]thiophene-2-sulfonamide Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=CC=C(Cl)S1 IXFIZZJAUYTVFQ-UHFFFAOYSA-N 0.000 claims description 2
- HEXLAVRQPAXCGQ-UHFFFAOYSA-N 5-chloro-n-[3-[(dimethylamino)methyl]-1h-indol-5-yl]-3-methyl-1-benzothiophene-2-sulfonamide Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)NC1=CC=C2NC=C(CN(C)C)C2=C1 HEXLAVRQPAXCGQ-UHFFFAOYSA-N 0.000 claims description 2
- VYGIFWOBSLDFGX-UHFFFAOYSA-N 5-chloro-n-[3-[2-(4-methylpiperidin-1-yl)ethyl]-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1CC(C)CCN1CCC(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=CC=CC2=C(Cl)C=CC=C12 VYGIFWOBSLDFGX-UHFFFAOYSA-N 0.000 claims description 2
- UOQACFXRHOYBLO-UHFFFAOYSA-N 5-chloro-n-[3-[2-(dibutylamino)ethyl]-1h-indol-5-yl]-3-methyl-1-benzothiophene-2-sulfonamide Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)NC1=CC=C2NC=C(CCN(CCCC)CCCC)C2=C1 UOQACFXRHOYBLO-UHFFFAOYSA-N 0.000 claims description 2
- JVYUJTOTNLYRGJ-UHFFFAOYSA-N 5-chloro-n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]-3-methyl-1-benzothiophene-2-sulfonamide Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)NC1=CC=C2NC=C(CCN(CC)CC)C2=C1 JVYUJTOTNLYRGJ-UHFFFAOYSA-N 0.000 claims description 2
- VBNSQPAQKREKCT-UHFFFAOYSA-N 5-chloro-n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(CC)CC)=CC=CC2=C1Cl VBNSQPAQKREKCT-UHFFFAOYSA-N 0.000 claims description 2
- NGSSZCPZKZXHLL-UHFFFAOYSA-N 5-chloro-n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]thiophene-2-sulfonamide Chemical compound C1=C2C(CCN(CC)CC)=CNC2=CC=C1NS(=O)(=O)C1=CC=C(Cl)S1 NGSSZCPZKZXHLL-UHFFFAOYSA-N 0.000 claims description 2
- ZHONXOSWPFCSGQ-UHFFFAOYSA-N 5-chloro-n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]-3-methyl-1-benzothiophene-2-sulfonamide Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)NC1=CC=C2NC=C(CCN(C)C)C2=C1 ZHONXOSWPFCSGQ-UHFFFAOYSA-N 0.000 claims description 2
- GRAZEJPPQICHTB-UHFFFAOYSA-N 5-chloro-n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(C)C)=CC=CC2=C1Cl GRAZEJPPQICHTB-UHFFFAOYSA-N 0.000 claims description 2
- OOIQBABUMXSCPC-UHFFFAOYSA-N 5-chloro-n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]naphthalene-2-sulfonamide Chemical compound ClC1=CC=CC2=CC(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(C)C)=CC=C21 OOIQBABUMXSCPC-UHFFFAOYSA-N 0.000 claims description 2
- WSSVKAAIGVWZQY-UHFFFAOYSA-N 5-chloro-n-[3-[2-(dipropylamino)ethyl]-1h-indol-5-yl]-3-methyl-1-benzothiophene-2-sulfonamide Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)NC1=CC=C2NC=C(CCN(CCC)CCC)C2=C1 WSSVKAAIGVWZQY-UHFFFAOYSA-N 0.000 claims description 2
- ACGFJJWYZNMORR-UHFFFAOYSA-N 5-chloro-n-[3-[3-(diethylamino)propyl]-1h-indol-5-yl]-3-methyl-1-benzothiophene-2-sulfonamide Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)NC1=CC=C2NC=C(CCCN(CC)CC)C2=C1 ACGFJJWYZNMORR-UHFFFAOYSA-N 0.000 claims description 2
- BKEVGLNYKZLFEH-UHFFFAOYSA-N 6-chloro-n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide Chemical compound C1=C2C(CCN(CC)CC)=CNC2=CC=C1NS(=O)(=O)C1=C(Cl)N=C2N1C=CS2 BKEVGLNYKZLFEH-UHFFFAOYSA-N 0.000 claims description 2
- RZAXUKVIIWUIOM-UHFFFAOYSA-N 6-chloro-n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1NS(=O)(=O)C1=C(Cl)N=C2N1C=CS2 RZAXUKVIIWUIOM-UHFFFAOYSA-N 0.000 claims description 2
- ZOUZXQXZZZMOLJ-UHFFFAOYSA-N n-[3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1N(C)CCC(C=2C3=CC(NS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)=CC=C3NC=2)=C1 ZOUZXQXZZZMOLJ-UHFFFAOYSA-N 0.000 claims description 2
- YOIWOMIOVRDSRT-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]-4-phenylbenzenesulfonamide Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=CC=C(C=2C=CC=CC=2)C=C1 YOIWOMIOVRDSRT-UHFFFAOYSA-N 0.000 claims description 2
- WUSDVPWNSLONFH-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=CC=CC2=CC=CC=C12 WUSDVPWNSLONFH-UHFFFAOYSA-N 0.000 claims description 2
- TVGKDKBOGMPNLH-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=CC=CC2=CC=CC=C12 TVGKDKBOGMPNLH-UHFFFAOYSA-N 0.000 claims description 2
- MLLKJGGUSYHRQW-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]quinoline-8-sulfonamide Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=CC=CC2=CC=CN=C12 MLLKJGGUSYHRQW-UHFFFAOYSA-N 0.000 claims description 2
- NYSFXFCXIDQEPV-UHFFFAOYSA-N n-[3-(2-morpholin-4-ylethyl)-1h-indol-5-yl]-4-phenylbenzenesulfonamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1S(=O)(=O)NC(C=C12)=CC=C1NC=C2CCN1CCOCC1 NYSFXFCXIDQEPV-UHFFFAOYSA-N 0.000 claims description 2
- WPRZEOAUFXLXPG-UHFFFAOYSA-N n-[3-(2-morpholin-4-ylethyl)-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)NC(C=C12)=CC=C1NC=C2CCN1CCOCC1 WPRZEOAUFXLXPG-UHFFFAOYSA-N 0.000 claims description 2
- GQVMAJQCWHEMNR-UHFFFAOYSA-N n-[3-(2-morpholin-4-ylethyl)-1h-indol-5-yl]naphthalene-2-sulfonamide Chemical compound C=1C=C2C=CC=CC2=CC=1S(=O)(=O)NC(C=C12)=CC=C1NC=C2CCN1CCOCC1 GQVMAJQCWHEMNR-UHFFFAOYSA-N 0.000 claims description 2
- DDAIWXAPNYOMNI-UHFFFAOYSA-N n-[3-(2-morpholin-4-ylethyl)-1h-indol-5-yl]quinoline-8-sulfonamide Chemical compound C=1C=CC2=CC=CN=C2C=1S(=O)(=O)NC(C=C12)=CC=C1NC=C2CCN1CCOCC1 DDAIWXAPNYOMNI-UHFFFAOYSA-N 0.000 claims description 2
- ICLYOGTUYWWVTN-UHFFFAOYSA-N n-[3-(2-pyrrolidin-1-ylethyl)-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)NC(C=C12)=CC=C1NC=C2CCN1CCCC1 ICLYOGTUYWWVTN-UHFFFAOYSA-N 0.000 claims description 2
- WWJUEGBQBBZAGT-UHFFFAOYSA-N n-[3-(2-pyrrolidin-1-ylethyl)-1h-indol-5-yl]naphthalene-2-sulfonamide Chemical compound C=1C=C2C=CC=CC2=CC=1S(=O)(=O)NC(C=C12)=CC=C1NC=C2CCN1CCCC1 WWJUEGBQBBZAGT-UHFFFAOYSA-N 0.000 claims description 2
- PYTOOTXFGYHOJJ-UHFFFAOYSA-N n-[3-[2-(4-methylpiperidin-1-yl)ethyl]-1h-indol-5-yl]naphthalene-2-sulfonamide Chemical compound C1CC(C)CCN1CCC(C1=C2)=CNC1=CC=C2NS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 PYTOOTXFGYHOJJ-UHFFFAOYSA-N 0.000 claims description 2
- ZMWFJTOJCAGXKR-UHFFFAOYSA-N n-[3-[2-(dibutylamino)ethyl]-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(CCCC)CCCC)=CC=CC2=C1 ZMWFJTOJCAGXKR-UHFFFAOYSA-N 0.000 claims description 2
- UIRIEFKMLBIEPD-UHFFFAOYSA-N n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]-4-phenylbenzenesulfonamide Chemical compound C1=C2C(CCN(CC)CC)=CNC2=CC=C1NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CC=C1 UIRIEFKMLBIEPD-UHFFFAOYSA-N 0.000 claims description 2
- CYRQMGSDPZJXOB-UHFFFAOYSA-N n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]-n-ethylnaphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)N(CC)C3=CC=C4NC=C(C4=C3)CCN(CC)CC)=CC=C21 CYRQMGSDPZJXOB-UHFFFAOYSA-N 0.000 claims description 2
- KTQHWSWXJVQQSQ-UHFFFAOYSA-N n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(CC)CC)=CC=CC2=C1 KTQHWSWXJVQQSQ-UHFFFAOYSA-N 0.000 claims description 2
- SHPWEOLFTNUCFL-UHFFFAOYSA-N n-[3-[2-(diethylamino)ethyl]-1h-indol-5-yl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C1=CC=C2C(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(CC)CC)=CC=CC2=C1 SHPWEOLFTNUCFL-UHFFFAOYSA-N 0.000 claims description 2
- JKOSQHWDQUDFSI-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]-2,1,3-benzothiadiazole-4-sulfonamide Chemical compound C1=CC2=NSN=C2C(S(=O)(=O)NC2=CC=C3NC=C(C3=C2)CCN(C)C)=C1 JKOSQHWDQUDFSI-UHFFFAOYSA-N 0.000 claims description 2
- GJMVQIFNKWHCSE-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]-4-phenoxybenzenesulfonamide Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1NS(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 GJMVQIFNKWHCSE-UHFFFAOYSA-N 0.000 claims description 2
- SNTNUEYGURUYLJ-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]-4-phenylbenzenesulfonamide Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CC=C1 SNTNUEYGURUYLJ-UHFFFAOYSA-N 0.000 claims description 2
- VIFGXFJFKMSNKU-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(C)C)=CC=CC2=C1 VIFGXFJFKMSNKU-UHFFFAOYSA-N 0.000 claims description 2
- MPZZPMPAWOTSIY-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(C)C)=CC=C21 MPZZPMPAWOTSIY-UHFFFAOYSA-N 0.000 claims description 2
- XPRKZGSAGJCUOL-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(C)C)=CC=CC2=C1 XPRKZGSAGJCUOL-UHFFFAOYSA-N 0.000 claims description 2
- LBWBRGTZCKDBNN-UHFFFAOYSA-N n-[3-[2-(dipropylamino)ethyl]-1h-indol-5-yl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(CCC)CCC)=CC=CC2=C1 LBWBRGTZCKDBNN-UHFFFAOYSA-N 0.000 claims description 2
- XHDVQKJVBJXDDG-UHFFFAOYSA-N n-[3-[2-(dipropylamino)ethyl]-1h-indol-5-yl]naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCN(CCC)CCC)=CC=C21 XHDVQKJVBJXDDG-UHFFFAOYSA-N 0.000 claims description 2
- YPQQPLDCWAKIGB-UHFFFAOYSA-N n-[3-[3-(diethylamino)propyl]-1h-indol-5-yl]naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC3=CC=C4NC=C(C4=C3)CCCN(CC)CC)=CC=C21 YPQQPLDCWAKIGB-UHFFFAOYSA-N 0.000 claims description 2
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 238000004519 manufacturing process Methods 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 8
- 229910052717 sulfur Chemical group 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- -1 1,2,3,6-tetrahydropyridin-4-yl group Chemical group 0.000 claims 2
- ZCBIFHNDZBSCEP-UHFFFAOYSA-N 1H-indol-5-amine Chemical compound NC1=CC=C2NC=CC2=C1 ZCBIFHNDZBSCEP-UHFFFAOYSA-N 0.000 claims 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical group O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 150000008050 dialkyl sulfates Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- IOJVMOAYKYBHST-UHFFFAOYSA-N n-[3-[(4-methylpiperazin-1-yl)methyl]-1h-indol-5-yl]-1-phenylmethanesulfonamide Chemical compound C1CN(C)CCN1CC(C1=C2)=CNC1=CC=C2NS(=O)(=O)CC1=CC=CC=C1 IOJVMOAYKYBHST-UHFFFAOYSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 0 CN(c1ccc2[n](*)cc(CC*)c2c1)S(*)(=O)=O Chemical compound CN(c1ccc2[n](*)cc(CC*)c2c1)S(*)(=O)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200102517A ES2187300B1 (es) | 2001-11-14 | 2001-11-14 | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
| PCT/ES2002/000518 WO2003042175A1 (es) | 2001-11-14 | 2002-11-08 | Derivados de sulfonamidas, su preparación y su aplicación como medicamentos |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009223711A Division JP5132649B2 (ja) | 2001-11-14 | 2009-09-29 | スルホンアミド誘導体類と、その製造方法及び医薬としての応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005513016A JP2005513016A (ja) | 2005-05-12 |
| JP2005513016A5 true JP2005513016A5 (enExample) | 2006-01-05 |
| JP4416505B2 JP4416505B2 (ja) | 2010-02-17 |
Family
ID=8499446
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003544012A Expired - Fee Related JP4416505B2 (ja) | 2001-11-14 | 2002-11-08 | スルホンアミド誘導体類と、その製造方法及び医薬としての応用 |
| JP2009223711A Expired - Fee Related JP5132649B2 (ja) | 2001-11-14 | 2009-09-29 | スルホンアミド誘導体類と、その製造方法及び医薬としての応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009223711A Expired - Fee Related JP5132649B2 (ja) | 2001-11-14 | 2009-09-29 | スルホンアミド誘導体類と、その製造方法及び医薬としての応用 |
Country Status (33)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2187300B1 (es) * | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
| JP2006525972A (ja) * | 2003-05-09 | 2006-11-16 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | 食物摂取障害の予防および／または治療用の医薬品製造のためのスルホンアミド誘導体の使用 |
| ES2222832B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2228268B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
| ES2222827B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2228267B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
| ES2222829B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222830B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| ATE430752T1 (de) * | 2004-01-02 | 2009-05-15 | Suven Life Sciences Ltd | Neue indenoä2,1-aüindene und isoindolä2,1-aüindol |
| ES2246721B1 (es) * | 2004-08-10 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos. |
| EP1632491A1 (en) * | 2004-08-30 | 2006-03-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted indole compounds and their use as 5-HT6 receptor modulators |
| ATE489138T1 (de) | 2005-04-13 | 2010-12-15 | Neuraxon Inc | Substituierte indolverbindungen mit nos-hemmender aktivität |
| JP5026690B2 (ja) * | 2005-11-21 | 2012-09-12 | 株式会社ジャパンディスプレイイースト | 表示装置 |
| NZ568910A (en) * | 2006-01-24 | 2011-04-29 | Lilly Co Eli | Indole sulfonamide modulators of progesterone receptors |
| EP1837332A1 (en) * | 2006-03-23 | 2007-09-26 | Laboratorios Del Dr. Esteve, S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
| ZA200809659B (en) * | 2006-04-13 | 2010-03-31 | Neuraxon Inc | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity |
| EP1902733A1 (en) * | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
| EP1953153A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
| EP1953141A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
| EP2018861A1 (en) * | 2007-07-26 | 2009-01-28 | Laboratorios del Dr. Esteve S.A. | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain |
| EP2020230B1 (en) | 2007-08-01 | 2011-01-19 | Laboratorios del Dr. Esteve S.A. | Combination of at least two 5-HT6-Ligands |
| EP2036888A1 (en) * | 2007-09-17 | 2009-03-18 | Laboratorios del Dr. Esteve S.A. | Naphthyl-substituted sulfonamides |
| WO2009062318A1 (en) * | 2007-11-16 | 2009-05-22 | Neuraxon, Inc. | 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
| US20090163451A1 (en) * | 2007-11-16 | 2009-06-25 | Frank Porreca | Methods for treating visceral pain |
| EA201000808A1 (ru) * | 2007-11-16 | 2011-04-29 | Ньюраксон, Инк. | Индольные соединения и способы лечения висцеральной боли |
| EP2116547A1 (en) | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands |
| EP2116546A1 (en) * | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands |
| CU24398B1 (es) * | 2013-08-02 | 2019-04-04 | Pfizer | 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2 |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472870A (en) * | 1966-08-29 | 1969-10-14 | Mead Johnson & Co | Sulfonamidotryptamines |
| US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| KR19980703048A (ko) * | 1995-03-20 | 1998-09-05 | 피터쥐.스트링거 | 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트 |
| US5962473A (en) * | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
| EP0875513A1 (en) * | 1997-04-14 | 1998-11-04 | Eli Lilly And Company | Substituted heteroaromatic 5-HT 1F agonists |
| US6380201B1 (en) * | 1997-08-05 | 2002-04-30 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists |
| ES2187300B1 (es) * | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
-
2001
- 2001-11-14 ES ES200102517A patent/ES2187300B1/es not_active Expired - Fee Related
-
2002
- 2002-08-11 UA UA20040604587A patent/UA78252C2/uk unknown
- 2002-11-08 AR ARP020104303A patent/AR037288A1/es not_active Application Discontinuation
- 2002-11-08 RS YU41104A patent/RS41104A/sr unknown
- 2002-11-08 WO PCT/ES2002/000518 patent/WO2003042175A1/es not_active Ceased
- 2002-11-08 IL IL16188502A patent/IL161885A0/xx unknown
- 2002-11-08 BR BR0214243-0A patent/BR0214243A/pt not_active IP Right Cessation
- 2002-11-08 NZ NZ533136A patent/NZ533136A/en unknown
- 2002-11-08 HU HU0402317A patent/HUP0402317A2/hu unknown
- 2002-11-08 SG SG200602676-9A patent/SG146442A1/en unknown
- 2002-11-08 HR HR20040429A patent/HRP20040429B1/xx not_active IP Right Cessation
- 2002-11-08 CN CNB028240804A patent/CN1271052C/zh not_active Expired - Fee Related
- 2002-11-08 KR KR10-2004-7007155A patent/KR20040071685A/ko not_active Ceased
- 2002-11-08 NZ NZ543393A patent/NZ543393A/en unknown
- 2002-11-08 DE DE60232029T patent/DE60232029D1/de not_active Expired - Lifetime
- 2002-11-08 SI SI200230302T patent/SI1445252T1/sl unknown
- 2002-11-08 PT PT02785439T patent/PT1445252E/pt unknown
- 2002-11-08 RU RU2004117850/04A patent/RU2293082C2/ru not_active IP Right Cessation
- 2002-11-08 EP EP05021228A patent/EP1666462B1/en not_active Expired - Lifetime
- 2002-11-08 CA CA2466965A patent/CA2466965C/en not_active Expired - Fee Related
- 2002-11-08 PL PL02373894A patent/PL373894A1/xx not_active Application Discontinuation
- 2002-11-08 DK DK02785439T patent/DK1445252T3/da active
- 2002-11-08 DE DE60209779T patent/DE60209779T2/de not_active Expired - Lifetime
- 2002-11-08 ES ES02785439T patent/ES2259387T3/es not_active Expired - Lifetime
- 2002-11-08 PT PT05021228T patent/PT1666462E/pt unknown
- 2002-11-08 MX MXPA04004601A patent/MXPA04004601A/es active IP Right Grant
- 2002-11-08 ES ES05021228T patent/ES2322068T3/es not_active Expired - Lifetime
- 2002-11-08 EP EP02785439A patent/EP1445252B1/en not_active Expired - Lifetime
- 2002-11-08 JP JP2003544012A patent/JP4416505B2/ja not_active Expired - Fee Related
- 2002-11-08 AT AT05021228T patent/ATE428694T1/de active
- 2002-11-08 AT AT02785439T patent/ATE319684T1/de active
- 2002-11-11 TW TW091132989A patent/TWI275585B/zh not_active IP Right Cessation
- 2002-11-13 US US10/293,206 patent/US7105515B2/en not_active Expired - Fee Related
-
2004
- 2004-05-06 ES ES200401084A patent/ES2249129B2/es not_active Expired - Fee Related
- 2004-05-13 EC EC2004005105A patent/ECSP045105A/es unknown
- 2004-05-13 IS IS7263A patent/IS7263A/is unknown
- 2004-05-25 ZA ZA200404073A patent/ZA200404073B/en unknown
- 2004-05-26 CO CO04048713A patent/CO5590895A2/es not_active Application Discontinuation
- 2004-06-07 MA MA27723A patent/MA27093A1/fr unknown
- 2004-06-14 NO NO20042478A patent/NO20042478L/no not_active Application Discontinuation
- 2004-09-03 US US10/933,951 patent/US7176200B2/en not_active Expired - Fee Related
-
2005
- 2005-11-22 RU RU2005136355/04A patent/RU2005136355A/ru not_active Application Discontinuation
-
2006
- 2006-06-02 CY CY20061100709T patent/CY1105362T1/el unknown
- 2006-07-17 US US11/487,745 patent/US7498328B2/en not_active Expired - Fee Related
-
2007
- 2007-02-16 US US11/707,571 patent/US7452881B2/en not_active Expired - Fee Related
- 2007-12-05 IS IS8698A patent/IS8698A/is unknown
-
2008
- 2008-08-04 IL IL193234A patent/IL193234A0/en unknown
-
2009
- 2009-09-29 JP JP2009223711A patent/JP5132649B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004117850A (ru) | Производные сульфонамида, их получение и применение в качестве лекарственных средств | |
| TW470743B (en) | Benzenesulfonamide derivatives, their preparation and their use in the treatment of CNS disorders | |
| CN101679287B (zh) | 烟碱型乙酰胆碱受体调节剂 | |
| WO2002012189A1 (en) | Fused bicyclic amide compounds and medicinal use thereof | |
| JP2004517072A (ja) | Ｃｎｓ障害の治療において有用な化合物 | |
| JP2011528372A (ja) | α７ニコチン性アセチルコリンレセプターインヒビター | |
| JP2020523388A5 (enExample) | ||
| JP2005518414A5 (enExample) | ||
| BRPI0318799B1 (pt) | Processo para a preparação de um composto | |
| CZ287381B6 (en) | Piperazine derivatives, processes and intermediates for their preparation, their use and pharmaceutical compositions based thereon | |
| PT1682503E (pt) | Derivados de n-( fenil ( alquilipiperidin-2il )mentil )benzamida, sua preparação e sua aplicação em terapêutica. | |
| JP2007500168A5 (enExample) | ||
| WO2007063925A1 (ja) | ２－アミノベンズアミド誘導体 | |
| TWI249402B (en) | 2,7-substituted indoles | |
| JPH08507067A (ja) | Ｈｉｖ逆転写酵素阻害剤 | |
| RU2006105777A (ru) | Индол-6-ильные сульфонамидные производные, их получение и их применение в качестве модуляторов 5-нт-6 | |
| JP2007500168A (ja) | １−スルホニルインドール誘導体、それらの調製及び５−ｈｔ６リガンドとしてのそれらの使用 | |
| JP6434528B2 (ja) | 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 | |
| RU2006105779A (ru) | Индол-5-ильные сульфонамидные производные, их получение и их применение в качестве модуляторов 5-нт-6 | |
| US9271980B2 (en) | Deuterium-enriched pyrimidine compounds and derivatives | |
| AU2014362381A1 (en) | Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors | |
| WO2012087182A3 (ru) | Замещенные метил-амины, антагонисты серотониновых 5-нт6 рецепторов, способы получения и применения | |
| JP4865710B2 (ja) | 情動障害、疼痛、ａｄｈｄおよび腹圧性尿失禁の治療に使用するための２−（１ｈ−インドリルスルファニル）−アリールアミン誘導体 | |
| US20090306144A1 (en) | Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents | |
| JP2008536841A (ja) | ３，４−ジヒドロ−ベンゾ［ｅ］［１，３］オキサジン−２−オン |